Asia: Intellectual Property

On April 21, the 2025 High-level Forum on China's Intellectual Property (IP) Protection was held in Beijing. The forum was co-hosted by China Intellectual Property News (CIPN) and World Intellectual Property Organization (WIPO) Office in China.

2025年4月26日是第25个"世界知识产权日"，同时，4月20日至4月26日也是我国的"全国知识产权周"。

April 26, 2025, marks the 25th "World Intellectual Property Day," and China also announced the "National Intellectual Property Week" from April 20 to April 26. In the wake of rapidly changing global situation...

When setting intellectual property strategy it pays to have a solid understanding of the prevailing business issues. In cleantech there are a number of diverse industries involved, with a trend towards convergence of technologies and sectors.

Software companies doing business in India have been put on notice by the Indian Income Tax Department following an unexpected outcome in the Income Tax Appellate Tribunal (Microsoft Corporation v. Assistant Director of Income-tax, International Tax Division).

Recently, there has been an increase in so-called "scams" involving apparent IP-related companies sending misleading letters to applicants and owners of IP rights in an attempt to extract money from those persons. A number of official intellectual property organisations, including the World Intellectual Property Organisation (WIPO), have recognised this issue and distributed warnings against these scams.

iiNet was once again successful in defending its position.

The Israeli Patent Office had previously adopted a restrictive standard in relation to computer implemented technologies.

The Full Federal Court has overturned the decision which legitimised the time shifting recording technology used by Optus.

The viewpoint of being able to provide cheap drugs to a population which cannot afford it has started yet another debate in the pharma sector about how drug companies should price the life saving drugs in the developing world.

In an eagerly awaited decision, India's Controller of Patents has granted a licence to generics pharmaceutical manufacturer, Natco Pharma Ltd (Natco) to manufacture Bayer's patented anticancer drug 'Naxavar'.

A Senate Committee has recommended against passing amendments to the Patents Act that would allow gene patenting.